Share |

Biotech / Health Articles

 et al.

A collaboration has formed in Montgomery County’s life sciences industry, Germantown-based Intrexon Corporation (NYSE: XON) and Rockville-based Synthetic Biologics Inc (NYSE: MKT) announced that the two companies will pursue an innovative biotherapeutics treatment for Phenylketonuria.

Phenylketonuria is a rare disease passed down genetically and happens at birth. Infants are born without the ability to properly break down an amino acid called phenylalanine. Symptoms include lighter skin and hair, seizures and abnormal motor and mental skills.

 et al.

Germantown, Md-based IntrexonCorporation (NYSE: XON) continues to fuel its growth by buying viable biotechnology companies. This time the bioindustrial focused company has entered an agreement to purchase Oxitec, a spin off from Oxford University in the United Kingdom, founded in 2002.

Oxitec uses genetic engineering to control insect pests and protect crops. The technonolgy is particulary focused on control the mosquitoes and the diseases they spread.

 et al.

After much thought and deliberation, the best course of action for Emergent BioSolutions (NYSE: EBS) was to spin-off its’ bioscience business into a separate publicly traded company. The new company doesn’t have a name yet (expected to be announced in early 2016) but the headquarters choice has been selected.

 et al.

The Gaithersburg, Md.-based biotech that came up with a faster and innovative way to produce vaccines has announced positive data from a Phase 2 trial focused on developing an Influenza vaccine.

 et al.

Treatment for chronic hepatitis B (CHB) has improved significantly in the last 10 years but despite those improvements  360 million people or 5 percent of the world’s population remain chronically infected by the Hepatitis B virus (HBV). That's according to Gaithersburg, Md-based Vaxin Inc, the company recently announced that it has initiated Phase 1 clinical stage trial to test a vaccine treatment for HepTcell, its' immunotherapeutic compound to treat people who are chronically infected with HBV.

 et al.

Rockville, Md-based MacroGenics, Inc. (Nasdaq:MGNX) announced that it has advanced in the development of its’ monoclonal antibody-based therapeutics drug to treat various types of leukemia. MGD011 (also known as JNJ-64052781) dosing has commenced in a Phase 1 trial in partnership with Janssen Biotech, Inc.

 et al.

Silver Spring, Md-based United Therapeutics Corporation (NASDAQ: UTHR) remained profitable and increased revenues in the second quarter of 2015 but despite the growth, the company fell short of exceeding key analyst estimates .

 et al.

Germantown, Md-based Neuralstem, Inc (Nasdaq: CUR) shares rose more 7 percent Thursday, opening at $1.75 a share and closing at $1.93 share.

The spike in the stock price was related to news that the company won a ruling in its favor for a patent infringement case.

Neuralstem was the defendant in the case filed against it by Palo Alto, Calif-based StemCells, Inc. The case was dismissed by the U.S. Federal District Court for the District of Maryland.

 et al.

Biodefense company Emergent BioSolutions (NYSE: EBS) won a large Biomedical Advanced Research and Development Authority (BARDA) contract to treat Ebola Monoclona.

The contract is the company's first BARDA Task Order to create an Ebola treatment under the Center for Innovation in Advanced Development and Manufacturing (CIADM) program. BARDA is an authority under the U.S. Department of Health and Human Services.

 et al.

Germantown, Md-based Qiagen Sciences (NASDAQ: QGEN) has received Food and Drug Adminstration approval to market it's therascreen EGFR testing kit in the United States.

 et al.

Washington, D.C.-based Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) announced that the European Union (EU) has approved its HETLIOZ (tasimelteon) drug to be used to treat non-24-hour sleep-wake disorder, also known as Non-24, in totally blind adults.

Non-24 is a chronic, circadian rhythm disorder. It disturbs the normal human sleep-wake cycle and mostly affects totally blind people. Disturbed sleep can lead to stress and also affects coordination. In the EU, around 130,000 people have been affected by this disorder.

 et al.

Gaithersburg-based GlycoMimetics (soon to be in North Rockville) received a another large payment from Pfizer.

GlycoMimetics (NASDAQ: GLYC) has entered its Phase 3 clinical trial called RESET (Rivipansel: Evaluating Safety, Efficacy and Time to Discharge) to treat people with sickle cell disease who are six years of age or older.

 et al.

Silver Spring, Maryland-based United Therapeutics Corporation (NASDAQ: UTHR) was the top gainer on Monday March 16, 2015, according to data from Google Finance biotechnology index. The fast growing company gained over $13 or 8.14% in a one-day trading session.

The stock price was already trading well over $170 for several days and has more than doubled from its 52-week low of $84.63.

 et al.

Silver Spring, Maryland-based United Therapeutics Corporation (NASDAQ:UTHR) is a biotechnology company with a primary focus on the creation of therapeutic drugs that treat pulmonary arterial hypertension (PAH). The company has four products on the market with the release of its' fourth drug Orenitram in mid 2014; after receiving FDA approval for it in December 2013.

 et al.

Washington, D.C.-based Vanda Pharmaceuticals Inc (NASDAQ:VNDA), has launched a couple of drugs and even recently put into place a television ad campaign. The company is now in need of extra space and will expand into an additional 8,600 square feet at its D.C. headquarters located at 2200 Pennsylvania Avenue.

Vanda will pay the landlord, Square 54 Office Owner LLC, and additional $381,000 for a 12 year and one month term lease beginning on September 1, 2014, although Vanda will get a nine month grace period.

 et al.

In late 2012 Sucampo Pharmaceuticals (NASDAQ: SCMP) received approval from the Food and Drug Administration (FDA)  to expand upon its gastrointestinal drug -- AMITIZA -- to treat people with opioid-induced constipation (OIC) in the United States.

With increasing competition from other biotechnology companies, that approval is keeping the Bethesda-based drug developer ahead of them and profitable, with a net income posted in 3 out of the last 4 quarters of 2013, including the most recent fourth quarter.

 et al.

Germantown, Maryland-based Intrexon Corporation (NYSE:XON) stock was recently upgraded by EVA Dimensions last week but that doesn’t explain yesterdays price surge of more than 10 percent for the company.

Intrexon was the third most price-trending stock on Google Finance yesterday, the stock price of the company increased more than 11.46 percent (+ $3.14) to close at $30.55 per share.

A few reasons that could have driven Intrexon’s stock price higher,

 et al.

In late 2012 Sucampo Pharmaceuticals (NASDAQ: SCMP) received approval from the Food and Drug Administration (FDA)  to expand upon its gastrointestinal drug -- AMITIZA -- to treat people with opioid-induced constipation (OIC) in the United States.

With increasing competition from other biotechnology companies, that approval is keeping the Bethesda-based drug developer ahead of them and profitable, with a net income posted in 3 out of the last 4 quarters of 2013, including the most recent fourth quarter.

 et al.

Silver Spring, Maryland-based United Therapeutics Corporation (NASDAQ:UTHR) crossed well over $1 billion in revenue for the first time in its corporate history and according to CEO Martine Rothblatt J.D., Ph.D., 2014 will be an even better year.

 et al.

Shareholders of Gaithersburg, Maryland-based GlycoMimetics Inc (NASDAQ:GLYC) are already enjoying 42 percent gains after the company went public in January. The stock started off at $8 per share and has climbed to a high of $13.37, achieved only yesterday.

There’s some speculation as to why the stock price jumped 21 percent on February 25th, rumors range from short interest to major news on the way.

 et al.

Germantown, Maryland is the farthest north of Montgomery County’s commercial centers, it’s also the smallest and youngest in terms of commercial development but that is quickly changing. With approximately 3 million square feet of office space, Germantown has been one of the county’s bright spots in terms of commercial development in the last couple of years.

 et al.

Saturday December 8th – 10am: Mike Tidwell, Executive Director of the Chesapeake Climate Action Network (CCAN), greeted a roomful of concerned citizens at the University of Baltimore.  The event they were attending was called Drilling Down: A Conference on Fracking Risks and Action in Maryland.  In the school&rsquo

 et al.

Rockville-based Catalyst Health Solutions (NASDAQ:CHSI), the fast growing prescription drug benefits provider, is in talks with Lisle, Illinois-based SXC Health Solutions (TSE:SXC) for a merger agreement valued at an estimated $4.4 Billion.

 et al.

Washington, D.C.-based Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) which recently moved its headquarters from Rockville, has purchased rights to develop and commercialize a small molecule neurokinin 1 receptor (NK-1R) antagonist called VLY-686. VLY-686 is being licensed from pharmaceutical giant Eli Lilly & Co (NYSE:LLY).

 et al.

Fairfax-based ICF International (NASDAQ:ICFI), will aid the Centers for Disease Control and Prevention (CDC) in studying "At-risk Youth".

Services will be provided to conduct two surveys and one study including the national Youth Risk Behavior Survey (YRBS), the National Youth Tobacco Survey (NYTS), and the School Health Policies and Practices Study (SHPPS). The government contractor will study health-risk behavior of middle and high school students

The $15.8 million contract will last over five years or 70 months

 et al.

Noted as Kaiser Permanente’s largest medical center in Montgomery County by Marilyn Kawamura, president, of Kaiser Foundation Health Plan of the Mid-Atlantic States, Inc; the 175,000 square foot office building overlooking I-270 is now operational and open to serve patients after over a year of renovations.

 et al.

Coventry Health Care, Inc. (NYSE: CVH) reported higher revenues but lower profits for the fourth quarter 2011 even with the positive impact of Medicare Advantage Private Fee-for-Service (MA-PFFS) product which added $0.02 to earnings per share.

 et al.

United Therapeutics Corporation (NASDAQ: UTHR)said it received notice from a generic drug manufacturer that it intends to release a remanufactured form of one of Silver Spring-based company's core drugs called Remodulin.

Sandoz Inc, submitted a Paragraph IV Certification Notice Letter which United Therapeutics received on February 3, 2012. The letter states that the company has sent an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) also in Silver Spring.

 et al.

Last week's announcement of Rockville-based Micromet's (NASDAQ:MITI) merger agreement with Thousand Oaks, Ca-based Amgen (NASDAQ:AMGN) was certainly big news for the region. It is one of the largest biotech acquisitions in the Mid-Atlantic and one of the largest acquisition announcements for any industry in the beginning of the new year.

 et al.

 

The fifth Vida Fitness center will open its doors to customers Tuesday, January 24 at 12:30 p.m.

The high-end gym Located at 445 K Street, NW, is at the ground floor of the City Vista residential-retail project which includes apartments above and is anchored by a Safeway grocery store. The two-level space was formerly occupied by a Results Gym.

 et al.

Rockville-based Vanda Pharmaceuticals (NASDAQ: VNDA) reported that it has sent notice to landlords of the Johns Hopkins University Montgomery County Campus for early termination of its office lease at 9605 Medical Center Drive.

 et al.

Biotechnology company, Emergent BioSolutions (NYSE:EBS) announced today that Abbott Laboratories (NYSE: ABT) has terminated an agreement between the two companies to develop and commercialize its TRU-016 program. The program is expected to eventually lead to the therapeutic drugs for lymphocytic leukemia and non-Hodgkin’s lymphoma.

 et al.

Silver Spring-based United Therapeutics Corporation (NASDAQ: UTHR) continues to expand into new markets with the French regulatory agency approval of the Intravenous form of its Pulmonary Arterial Hypertension drug Remodulin.

 et al.

Biodefense firm, PharmAthene, Inc. (NYSE Amex: PIP) announced that the Delaware Court of Chancery has denied competitor SIGA Technologies an appeal to the Court's decision on September 22, 2011.

With that ruling PharmAthene will receive 50 percent of net profits from the sale of ST-246, a smallpox antiviral drug being sold by SIGA. PharmAthene will receive the profits for 10 years after the first $40 million is accrued by SIGA. In addition, SIGA will pay one-third of attorney fees and witness costs.

 et al.

The next time you go under the knife, or a soldier returns home after being wounded in action, you might want to thank SimQuest – a company behind a variety of medical training simulations and software solutions custom-designed for their clients. Founded in 2001 by renowned surgeon Howard Champion, MD, SimQuest has three product lines – simulation, gaming and training, and trauma data analysis.

 et al.

Rockville-based, Micromet, Inc. (NASDAQ: MITI), has started the phase 2 trial of its lymphoblastic leukemia drug, blinatumomab (MT103). Blinatumomab utilizes the body’s T cells to kill cancer cells; it is classified as a new group of agents called BiTE® antibodies.

The drug is targeting adult patients with relapsed B-precursor acute lymphoblastic leukemia or (ALL).

 et al.

Nabi Biopharmaceuticals (Nasdaq:NABI) is recovering from its failed Phase III nicotine addiction drug trial back in July. The biotechnology company based in Rockville reported improved earnings for the third quarter ended September 26, 2011. It narrowed its net loss to $2.9 million or $-0.07 cents per share from $5.1 million or $-0.12 cents per share in third quarter of 2010 and $4.6 million in the second quarter ended June 26, 2011.

 et al.

Rockville-based Catalyst Health Solutions, Inc. (NASDAQ: CHSI) saw revenues jump an astounding 55 percent in the third quarter ended September 30, 2011. The nation's fastest growing pharmacy benefit manager announced revenues growth of $504.3 million to $1.43 billion versus $925.1 million in the third quarter of 2010.

The huge revenue growth comes after the acquisition of Walgreens Health Initiatives (WHI) by Catalyst in the spring of 2010. Revenues were slightly below the average estimate of 16 analysts which came to $1.45 billion.

 et al.

Bethesda-based Coventry Health Care, Inc. (NYSE: CVH), a Fortune 500 company healthcare provider, reported earnings in the third quarter ended September 30, 2011 that exceeded analyst estimates.

 et al.

Silver Spring-based United Therapeutics Corporation (NASDAQ: UTHR), the largest independent biotechnology company in the Baltimore-Washington area measured by market value, announced financial results today that far exceeded  analyst estimates.

In the third quarter ended September 30, 2011, United Therapeutics reported total revenues of $201.7 million, a year-over-year increase of 20 percent from $168.6 million. Revenues beat the average analyst estimate of $194.77 million.

 et al.

Bethesda-based Coventry Health Care, Inc. (NYSE: CVH), has agreed to purchase the Medicaid health plan business of Children's Mercy's Family Health Partners.

Kansas City-based Children's Mercy's Family Health Partners is managed by Children's Mercy Hospital. The group has an estimated 210,000 Medicaid total members with 155,000 members in the State of Kansas and the remaining members in the State of Missouri. The company brings in annual revenues of $450 million.

 et al.

Rockville-based Human Genome Sciences, Inc. (Nasdaq: HGSI) which launched Benlysta -- the first Lupus Drug in 56 years -- reported full quarter sales of it first consumer product.

The biotechnology company that partnered with GlaxoSmithKline PLC (NYSE: GSK) for Benlysta development said U.S. gross sales of the drug amounted to $21.3 million; net sales of the product were $18.8 million. That compares with $7.8 million of Benlysta sales in second quarter of 2011 although product delivery was not at full strength.

 et al.

Fairfax-based ICF International (NASDAQ: ICFI) was awarded a $34.3 million contract by the U.S. Department of Health and Human Services, Administration for Children and Families, Office of Head Start (OHS).

 et al.

Silver Spring-based United Therapeutics (NASDAQ: UTHR) subsidiary, Unither Virology, LLC has just been awarded a contract from the National Institutes of Health's (NIH), National Institute of Allergy and Infectious Diseases (NIAID) division.

The Montgomery County biotech will receive a $45 million contract over five years, including a 42-month base period that will fetch approximately $10.6 million in funding. Eight milestone-based options are part of the remaining funds.

 et al.

With a potential 1,500 new jobs on the way, Montgomery County Government sought it fit to ensure a successful launch of a new 93-bed Holy Cross Hospital proposed for the Germantown area of the County.

Montgomery County Executive Isiah Leggett announced that the planned Holy Cross Hospital is the first Strategic Economic Development Project. To make it official Leggett signed Executive Order 173-11, Designation of Strategic Economic Development Projects.

 et al.

Arguably one of the most diverse regions in the nation in overall racial and ethnic demographics, it is confident to declare the Baltimore/Washington area -- at least -- the top three in diversity when it comes to the number of high-level professionals involved in the health industry from different racial and ethnic backgrounds.

 et al.

No one knows more about wasteful spending than the government, and healthcare is on top of most people’s list when it comes to wasteful spending. Since 2009 the focus has shifted towards bringing down the cost of healthcare spending.

 et al.

One of the largest and most profitable biotechnology companies in the Mid-Atlantic is trying to increase its revenue by developing an oral form of treatment for pulmonary arterial hypertension (PAH).

Silver Spring-based United Therapeutics Corporation (NASDAQ: UTHR) released its FREEDOM-C(2) Phase 3 clinical trial results today but the company announced that the study did not meet its primary endpoint.

 et al.

Rockville-based Catalyst Health Solutions (NASDAQ:CHSI) Chief Executive Officer, David Blair made the following,

Blair acquired 52,500 common stock shares at an average price of $6.62, for a total of 371,095 beneficially owned shares August 16, 2011.

Blair disposed of 52,500 common stock shares at an average price of $53.07 with 318,595 Beneficially Owned shares remaining August 16th, 2011.

 et al.

Rockville-based Emergent BioSolutions Inc. (NYSE:EBS) has started Phase 1b/2 clinical trials study for a new drug that it hopes will aid patients in the treatment of lymphoma.

The treatment labeled TRU-016, will be administered in combination with Rituximab and Bendamustine in patients who have relapsed from indolent B-cellLymphoma.

 et al.

Rockville-based Nabi Biopharmaceuticals (Nasdaq:NABI) has added to its cash stockpile by obtaining $5 Million in milestone payments from Fresenius USA Manufacturing, Inc.

 et al.

PharmAthene, Inc. (AMEX: PIP), an Annapolis based biodefense company, announced that they have been awarded $5.7 million by the Department of Defense (DoD) to continue research of its nerve agent medical countermeasure program.

The contract will allow PharmAthene to evaluate mammalian cell-based manufacturing system for rBChE for a period of 18 months. The company indicated that if the research is successful, it could increase production, flexibility, and be cost-effective.

 et al.

Bethesda-based Northwest Biotherapeutics (OTC: NWBO) released a statement to give surety to Investors that its DCVax drug, will not run into the same issues currently facing Seattle, Washington-based, Dendreon Corporation's (NASDAQ:DNDN) Provenge immune therapy drug.

 et al.

Annapolis-basedbiodefense company PharmAthene, Inc. (NYSE Amex: PIP), increased revenue and reduced losses in the second quarter ended June 30, 2011.

Revenue totaled $6.4 Million in the quarter a year-over-year increase versus $4.8 Million in 2010. The increase was due to U.S. government funding for PharmAthene's  SparVax and Valortim biodefense drug programs.

 et al.

Two Rockville-based firms involved in drug development have teamed up to develop a new Tuberculosis (TB) vaccine.

Aeras a non-profit focused on developing vaccines to prevent TB and Emergent BioSolutions a biotechnology firm mostly known for its Antrax drug--BioThrax--are now entering a Phase IIb Proof-of-Concept Trial of Emergent's Modified Vaccinia virus Ankara--Antigen 85Abased TB vaccine.

 et al.

Cel-Sci Corporation (NYSE AMEX: CVM)with headquarters in Vienna, Va.,posted a net loss for Q2 2011, nearly six times deeper than in the second quarter of 2010.

Losses were $3.11 Million in the three-months quarter ended June 30, 2011 compared to $601,124 in 2010.

Revenue in the second quarter came entirely from grants and totaled a small sum of $77,403.

The company's expenses grew to $4.85 Million from $3.4 Million.

 et al.

Columbia-based Osiris Therapeutics, Inc. (NASDAQ:OSIR), Inc has filed its condensed financial statements for the six months ended June 30, 2011 and 2010.

The detailed report includes financial data for the second quarter of 2011 as well as a documented history of the company.

The link to the sec file—10-Q quarterly report—can be found by clicking here.

 et al.

Stella went into the hospital with a pain so great it cripples her entire being.  “It feels like a stabbing needle pain that shoots through my joints” she said.  No longer able to carry on her day to day routine she finally gives in after a few pills of over-the-counter pain medication did not work, and heads to the emergency room.  Her body is used to taking high doses of pain medication to alleviate the pain, so no regular pill will work.  The doctors and nurses in the hospital are too familiar with the patient; the only

 et al.

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), a biotechnology firm in Bethesda is taking on multiple matters to keep its revenue stream growing.

Chairman and Chief Executive Officer, Ryuji Ueno, M.D., Ph.D., Ph.D., said in a statement during its second quarter 2011, financial results that the company has filed a marketing application in the U.K. for approval of its drug lubiprostone to treat chronic idiopathic constipation.

 et al.

Bethesda-based Chindex International, Inc. (NASDAQ: CHDX), which hit a slight bump last quarter—posting a net loss—got back on track in the second quarter ended June 30, 2011.

Chindex conducts business a little differently and generates the majority of its income by providing health care services in China through its subsidiary United Family Healthcare. The company owns a network of hospitals that give private primary care. Its Beijing UFH hospital is currently undergoing an expansion.

 et al.

Fresh off an approval of Benlysta by the European Commission (EC) to sell the first Lupus drug in 56 years— Human Genome Sciences (NASDAQ: HGSI) next strategy is to make sure they can meet projected worldwide demand that could soar to revenues as high as $6 Billion annually.

 et al.

Rockville-based Emergent BioSolutions Inc. (NYSE: EBS) released another quarter of net income increases, dispelling the anecdotal evidence of unprofitable biotechnology companies in the region.

Net income jumped to $14.21 Million in the second quarter ended June 30, 2011 opposed to a net income of $9.81 Million in the prior quarter of 2010.

 et al.

Owings Mills-based Medifast, Inc. (NYSE: MED), reported another increase in net income for their second quarter.

As of June 30, 2011, the Baltimore County weight loss program company delivered $5.94 Million ($0.41 cents per diluted share) in profit, off of a 17% increase in revenue. That's compared to $5.54 Million ($0.38 cents per diluted share) in net income the same time last year.

 et al.

Rockville-based Micromet, Inc reported financial results for the second quarter of 2011 ended June 30.

The biotechnology company developing new treatments for cancer said revenues totaled $7.062 Million in the quarter, a small increase from $6.5 Million in the second quarter ended the same time last year.

Net loss widened by a large margin falling over $13 Million to $17.3 Million ($-0.19 cents per basic and diluted share) in the quarter versus a net loss of $4.062 Million ($-0.05 cents per basic and diluted share) in 2010.

 et al.

Vanda Pharmaceuticals Inc., (NASDAQ: VNDA) which recently announced it would be moving its headquarters to 2200 Pennsylvania Avenue, N.W. in Washington, D.C., released disappointing financial results for the second quarter ended June 30, 2011.

Revenues plunged 28% to $14.9 Million in the six months ended June 30, 2011 from $20.7 Million at the end of June 30, 2010, a $5.78 Million difference.

A net loss of $1.2 Million was reported by the Rockville based company for the first half of the year.

 et al.

The fastest-growing national Prescription Drug  Benefits Manager in U.S., continued another quarter of revenue topping $1 Billion. Catalyst Health Solutions, Inc. (NASDAQ: CHSI),  sales were well above the $1 Billion threshold with results showing over $1.23 Billion for the second quarter ended June 30, 2011.

Net income fell to $12.3 Million or $0.25 per diluted share from $19.4 Million $0.44 per diluted share.

 et al.

Rockville based Vanda Pharmaceuticals will take its schizophrenia drug Fanapt to South America where it will partner with Biotoscana Farma S.A. in an exclusive license agreement for marketing and selling of the drug in Argentina.

 et al.

Silver Spring based United Therapeutics Corporation(NASDAQ: UTHR) said its still on track to reach revenues of $750 Million by the end of the year. Revenues for the second quarter of 2011 amounted to $183.8 Million a significant increase from 2010 second quarter where revenues were $134.7 Million.

 et al.

First Potomac Realty Trust (NYSE: FPO), based in downtown Bethesda announced that CareFirst BlueCross BlueShield will extend its lease of 204,000 square-feet for its D.C. headquarters.

The 12 story building is located at 840 First Street, NE in the NoMa (North of Massachusetts Avenue) district. The largest health care insurer in the Mid-Atlantic region will continue to be the anchor tenant.

 et al.

James P. Kelly , Senior Vice President, Chief Financial Officer, Secretary, and Treasurer of Vanda Pharmaceuticals Inc (NASDAQ:VNDA) filled the following July 27, 2011.

 et al.

Schizophrenia drug maker Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) said its Marketing Authorization Application (MAA) has been accepted by the European Medicines Agency.

The Rockville, Md biotechnology company which won a surprising approval for its Fanapt (Iloperidone) schizophrenia drug in May 2009 is trying to sell the oral version of the drug in the European Union.

 et al.

After more than a decade of research, development, and waiting more than a year for a delayed FDA approval, Human Genome Sciences, Inc (NASDAQ: HGSI) finally has a drug on the market that it can consistently sell to the healthcare industry.

The Rockville, Md biotechnology company reported Benlysta net sales of $7.8 Million. $1.2 Million in additional sales were excluded due to non-delivery to healthcare providers prior to the release of second quarter financial results.

Increasing Lupus Drug Sales

 et al.

Typically the final stage before a drug is presented for FDA approval and gets the marketing and sales go ahead; the Phase III clinical trials for Nabi Biopharmaceuticals' NicVAX drug may be its' last stop for good.

The Rockville based biotechnology company said that  Nicotine Conjugate Immunotherapeutic (NicVAX) did not meet the primary endpoints in the first trial in its Phase III study.

 et al.

Another area based biotechnology company has partnered with a company on the other side of the country, a much larger company, far, far away from here.

This time it's Rockville based Micromet, Inc.

Micromet, Inc labels itself as a biopharmaceutical company focused on finding treatments for cancer through commercialization of innovative antibody based therapies. The company traces its root back to 1993 in Munich, Germany where a small group of scientists set upon treating cancer via T cell based therapies.

 et al.

Vienna based Cel-Sci Corporation (NYSE AMEX: CVM) said it has modified its licensing agreement with Israel based Teva Pharmaceutical Industries Ltd.

The agreement will now include eastern European country Croatia and the nation of Serbia in addition to the countries, Israel and Turkey.

The joint venture centers around Cel-Sci's experimental cancer treatment drug called Multikine. Pharmaceutical giant Teva will be responsible for marketing and fees associated with selling Multikine. Profits and revenue will be divided between Teva and Cel-sci.

 et al.

Annapolis based biotechnology company PharmAthene, Inc has reached a pivotal milestone in its development of an Anthrax prevention drug.

The biodefense biotech said that its SparVax™ rPA Anthrax Vaccineachieved a 36 month final product stability.

 et al.

Press Release

Micromet Announces Solid Tumor BiTE Antibody Collaboration with Amgen

- Collaboration on up to three targets and two programs
- Upfront payment of EUR 10 million upon deal execution
- Maximum deal value of EUR 695 million plus royalties and development cost reimbursement

ROCKVILLE, Md., Jul 11, 2011 (BUSINESS WIRE) --

 et al.

Press Release

"Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Probiomed S.A. de C.V. for Commercialization of Fanapt(TM) in Mexico

 et al.

The Richard M. Schulze Foundation made an equity investment in Bethesda based Northwest Biotherapeutics, Inc.

The microcap biotech received $4.55 million from the foundation on June 28th, 2011.

Currently in Phase III of its leading drug DCVax -Prostate, as the name implies, the treatment was developed as a new way to battle prostate cancer.

 Northwest focuses on creating treatments using personalized medicine techniques, the company moved to Montgomery County, Maryland from the Seattle, Washington area in 2007.

 et al.

The recent Walgreens Health Initiatives acquisition by Catalyst Health Solutions, Inc (NASDAQ: CHSI)  has already propelled the company's projected revenues to nearly double for the 2011 reporting year.

The Rockville based pharmacy benefit manager has updated its financial outlook and plans to bring in between $5.1 and $5.3 Billion, an increase of 35% to 41%.

 et al.

Over 15,626 attended the 2011 BIO International Conference surpassing last year's conference held in Chicago. Visitors from 48 states and 65 countries patronized the event.

As of June 28th, 2011 the BIO Business Forum fostered 21,183 meetings compared to 17,143 in Chicago.

2,410 companies featuring 157 presentations occurred at the Walter E. Washington Convention Center.   

 et al.

The Brilliant Achievement Award was presented to Human Genome Sciences CEO Thomas Watkins at the 16th Annual Chinese Biopharmaceutical Association Conference.

"The CBA Brilliant Achievement Award is given to honor outstanding individuals who have made significant contributions to science, technology, or business development in the bio pharmaceutical fields." said Zhifeng Long, Ph.D. Chair of the Conference Organizing Committee who was also honored and name President of the CBA for 2011 - 2012.

 et al.

Maryland Senator Nancy J. King received the award for outstanding leadership in advancing biotechnology.

The 2011 BIO Legislator of the Year Award was presented to her in front of County Executive Isiah Leggett and Tom Watkins, CEO of Human Genome Sciences as well as other political figures and biotechnology executives.

Christian Johansson, Maryland Secretary of Business and Economic Development presented the award to King with an honoring speech.

 et al.

At the 2011 BIO International Convention being held throughout this week in Washington, D.C., Montgomery County Executive Isiah Leggett made a special announcement for the funding of a tax credit exclusively for biotechs.  

"...Montgomery County will provide a local fund of one million dollars in biotech credit for those businesses in Montgomery County" declared Leggett in front of an audience at the Bio Maryland exhibit.

 et al.

The Chinese Biopharmaceutical Association held its annual event Sunday at the University System of Maryland, Shady Grove Campus in Rockville.

The 16th annual event for the association was represented by a large number of executives from China as well as the United States. The organization's members include scientists, attorneys, entrepreneurs and other professionals. More than four delegations in groups of ten or more attended the event, flying all the way from China.

 et al.

Qiagen N.V. with U.S. divisions in Germantown and Gaithersburg has extended an offer to purchase France based Ipsogen S.A.

The exclusive negotiations include a 47% preliminary stake, afterwards, Qiagen plans to purchase the remaining shares in Ipsogen.

Ipsogen is a cancer profiler, the company develops tests that guide patients and doctors through mapping diseases. The purchase fits in with Qiagen which also develops tests in the form of sample and assay technologies which help biomedical researchers and companies process and isolate DNA, RNA and proteins.

 et al.

Biotechnology firms have been reported to be hard hit by the recent recession; struggling to stay afloat amid a dearth of venture capital funding and and lack of new drugs selling on the market. The Biotech industry is often pigeonholed as frail, cash strapped and high risk; spending years on research to develop drugs but often ending with failure and bankruptcy.

But in Maryland it's a different story. Several biotech firms have achieved profitability for their full fiscal year and some of them for the first time in the midst of a troubled U.S. economy.